drugset / Trial / NCT01661283
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2
Completed
25 enrolled
Sarcoma Alliance for Research through Collaboration
Genentech, Inc. · collabNovartis Pharmaceuticals · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
To determine the clinical response rate of everolimus in combination with bevacizumab for patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated malignant peripheral nerve sheath tumor (MPNST). To evaluate the toxicity and safety of everolimus in combination with bevacizumab in individuals with MPNST
Timeline
- Start
- 2012-09
- Primary completion
- 2017-06
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Everolimus | Small molecule | 10 mg | — |